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Abstract
Background: WHO identifies pregnant women to be at increased risk for severe outcomes from influenza virus
infections and recommends that they be prioritized for influenza vaccination. The evidence supporting this,
however, is inconsistent. Ecologic studies in particular suggest more severe outcomes from influenza infection
during pregnancy than studies based on individual patient data. Individual studies however may be underpowered
and, as reported in a previous systematic review, confounding factors could not be adjusted for. We therefore
conducted an individual participant data meta-analysis to assess the risk for severe outcomes of influenza infection
in pregnant women while adjusting for other prognostic factors.
Methods: We contacted authors of studies included in a recently published systematic review. We pooled the
individual participant data of women of reproductive age and laboratory confirmation of influenza virus infection.
We used a generalized linear mixed model and reported odds ratios (OR) and 95% confidence intervals (CI).
Results: A total of 33 datasets with data on 186,656 individuals were available, including 36,498 eligible women of
reproductive age and known pregnancy status. In the multivariable model, pregnancy was associated with a 7
times higher risk of hospital admission (OR 6.80, 95%CI 6.02–7.68), among patients receiving medical care as in- or
outpatients, pregnancy was associated with a lower risk of admission to intensive care units (ICU; OR 0.57, 95%CI
0.48–0.69), and was not significantly associated with death (OR 1.00, 95%CI 0.75–1.34).
Conclusions: Our study found a higher risk of influenza associated hospitalization among pregnant women as
compared to non-pregnant women. We did not find a higher mortality rate or higher likelihood of ICU admission
among pregnant women who sought medical care. However, this study did not address whether a true
community based cohort of pregnant women is at higher risk of influenza associated complications.
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Background
Pregnancy is considered to be an important risk factor
for severe influenza-associated illness [1–3]. During the
2009 H1N1 influenza pandemic, pregnant women in the
United States had high rates of hospitalization; despite
representing only 1.0% of the population, pregnant
women accounted for 5.8% of the deaths associated with
the 2009 H1N1 influenza virus [1, 2]. Citing such disease
burden data, favorable influenza vaccine performance,
and availability of vaccine delivery platforms globally,
the World Health Organization (WHO) has prioritized
pregnant women for vaccine receipt [3].
Two systematic reviews conducted by three of the co-
authors (DM, JRO, ML), however, questioned whether
pregnancy confers an increased risk for severe influenza
illness: beyond increasing the need for hospitalization,
pregnancy was not associated with more severe influ-
enza associated outcomes in studies where exposure to
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influenza and outcomes are measured in individuals, in-
cluding admission to an intensive care unit (ICU), and
death [4, 5]. These findings differ from those of eco-
logical studies, where infection by influenza was as-
sumed but not directly measured, most of which
suggested more severe outcomes from influenza infec-
tion [5]. A critical concern is that prior vaccine expos-
ure, age, underlying health conditions, or antiviral
treatments may be different between pregnant women
and non-pregnant women of reproductive age hospital-
ized with influenza, particularly during the 2009 pan-
demic, which may have confounded the systematic
reviews that only analyzed aggregate, study-level data.
To explore the potential influence of confounding, we
obtained individual participant-level data (IPD) from
studies of reproductive age women with confirmed preg-
nancy status who had laboratory confirmed influenza
virus infection, and conducted a multivariable, IPD
meta-analysis to assess the odds of severe influenza out-
comes (defined as influenza-associated mortality, ICU
and hospital admission) among pregnant women com-
pared to non-pregnant women, adjusting for demo-
graphic, comorbid, and clinical covariates.
Methods
Search strategy and selection criteria
The eligibility criteria, co-variates of interest and ana-
lyses plan were defined a priori.
We requested de-identified IPD from corresponding au-
thors of studies included in our prior systematic reviews,
at varying levels of observation, including community,
hospital, and ICU [4, 5]. Studies were considered con-
ducted in a ‘community’ setting if participants were seek-
ing health care but have not yet been admitted to a
hospital. The search strategy and study selection were re-
ported previously. In short, we searched MEDLINE,
CINAHL, Global Health, and the Cochrane Central Regis-
ter of Controlled Trials from inception up to April 2014
[4, 5]. Ethics approval was obtained where needed by the
investigators providing IPD.
Eligible study designs included cohort as well as case
control studies published in English, French, Spanish, and
German, and must have reported IPD on pregnancy as a
risk factor for influenza-associated mortality (primary out-
come) and/or influenza associated hospitalization and/or
ICU admission (secondary outcomes). Previous systematic
reviews included pneumonia as an outcome, however,
given its inconsistent definition and rare reporting, we de-
cided a priori to exclude pneumonia as an outcome of
interest [4, 5]. Women with influenza virus infection and
of reproductive age (defined as 15–45 years) with known
pregnancy status were included in this analysis. Influenza
virus infection was confirmed through laboratory tests
(pre−/post-season or acute−/convalescent serology, viral
culture, nucleic acid amplification testing, or influenza
antigen detection).
Data extraction and quality assessment
All datasets were compared with the published results
and checked for missing or potentially invalid data. Dis-
crepancies were discussed with the study authors. Study
quality was assessed independently and in duplicate
using the Newcastle-Ottawa Scale [6] as previously re-
ported [4, 5]. We did not exclude studies based on study
quality.
Data synthesis and analysis
For the primary analyses, we only considered covariates
with less than 20% missing data across all studies (‘core
variables’). We chose the 20% threshold to balance be-
tween excluding potentially relevant risk factors from
the multivariable model with excessive missing data, but
simultaneously preserving sample size at both the par-
ticipant and study level. These ‘core variables’ were: age,
antiviral usage, diabetes mellitus, cardio-respiratory dis-
eases, immunocompromised status, and influenza vac-
cination status as defined in the original studies.
Vaccination status was only included for ICU admission
in a sensitivity analysis due to more than 20% missing
data. We conducted a one-stage IPD meta-analysis. First,
we run univariate analyses using a generalized linear
mixed model (GLMM) with the participant level as a
fixed effect and the study level as a random effect. We
calculated odds ratios (OR) and associated 95% confi-
dence intervals (CI). For the multivariable analyses, all
core variables were included. Furthermore, we con-
ducted post-hoc subgroup analyses separating study
populations enrolled in the community and in hospital-
ized patients, respectively. In a secondary analysis, we
added the following covariates with > 20% missing data
that had been excluded from the primary analysis but
were of potential relevance one by one to the primary
model: obesity, smoking status, chronic respiratory dis-
eases alone instead of the composite of cardiac-respira-
tory co-morbidities, as well as vaccination status for ICU
admission. We also considered this as a sensitivity ana-
lysis for pregnancy as a risk factor by testing the robust-
ness of our findings when adding additional potential
confounders. We did not plan to conduct a subgroup
analysis based on influenza season as we anticipated,
based on the original systematic review, that there would
be sparse data for seasons other than the 2009 H1N1
pandemic. We used PASW Statistics 18 and SAS/STAT
9.4 for analysis. Given the low event rate, we are using
the term ‘risk’ throughout the text when discussing ORs
to improve readability. Age was treated as a continu-
ous variable and odds were reported per 5-year
increase in age.
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Patient and public involvement
There was no patient/public involvement.
Results
A total of 33 [7–42] data sets of 142 (23.2%) studies
found to be eligible in the previously published system-
atic reviews were obtained (Fig. 1) [4, 5]. The most com-
mon reasons for not being able to obtain IPD were: no
response from the authors, or the authors not being able
to share the data. We received additional data that were
either unpublished, or of which only a subset of the data
had been published († in Table 1). Overall, data on 186,
656 individuals were available; 31.0% of a total of 31.0%
of 610,782 individuals included in the previous system-
atic review [5]. The average number of eligible partici-
pants per study was smaller in our dataset (n = 1106)
than in studies that had not been shared (n = 1685).
Otherwise, the study characteristics were similar be-
tween included and excluded studies: The median New-
castle-Ottawa score was 6 (interquartile range 6–7) in
each group. Similarly, 11/33 (33.3%) of included studies
were from low- and middle-income countries as com-
pared to 33/110 (30.0%) in excluded studies, and a co-
hort study design was the most common design (31 of
33 (93.9%) in included studies compared to 103/110
(93.6%) in excluded studies). Nucleic acid amplification
testing was used for the case definition in all studies
with data provided for this analysis, with the exception
of two studies which used any positive influenza test for
case confirmation (e.g. rapid testing, culture) [10, 36].
Studies were conducted in North America, Southern
America, Europe, Asia as well as Australia. No studies
were available from Africa. Finally, only three datasets
included not only patients infected during the 2009
H1N1 pandemic (proportion of US [7–9] and Canadian
Public Health data [10] and unpublished data from
Nishioka et al. from Brazil).
We had IPD of 43,837 (23.5%) women of reproductive
age (15–45 years of age). Pregnancy status was unavail-
able for 7339 (16.7%), leaving us with a total of 36,498
eligible participants. Nine studies with a total of 27,993
(76.7%) patients were conducted in a community setting,
20 studies with a total of 8013 (22.0%) enrolled patients
that were admitted to the hospital, and 4 studies with
492 (1.3%) patients included patients in an ICU setting,
only. Influenza vaccination status was missing in 11.9
and 6.6% of participants with influenza-associated mor-
tality and hospital admission outcomes, respectively, and
it was missing in 48.3% of participants with ICU admis-
sion as an outcome. Missing data in the other core vari-
ables ranged from 7.1 to 19.1% of participants
depending on outcome of interest. Among variables for
secondary outcomes, obesity status was missing in 36.3
to 54.5%, smoking status in 16.6 to 86.9%, and chronic
respiratory comorbidity in 7.4 to 21.1%.
The 4379 pregnant women (12.0%) were significantly
younger (mean 26.7 years) compared to non-pregnant
women (mean 29.2 years; mean difference 2.43, 95% CI
2.23–2.64) (Table 2). Antiviral treatment (55.4% in preg-
nant versus 28.7% in non-pregnant women; OR 3.09,
95% CI 2.88–3.31) and receipt of the influenza vaccine
(12.1% versus 7.8%; OR 1.62, 95% CI 1.44–1.82) were
more common in pregnant women. The prevalence of
co-morbidities was similar in both groups with the ex-
ception of immunosuppression, which was significantly
less common in pregnant women (1.96% versus 2.84%,
OR 0.69, 95% CI 0.54–0.87).
Influenza-associated mortality
All 33 included studies reported on influenza-associated
mortality with outcome data available for 36,489 partici-
pants. Data from Kusznierz et al. [21] was a subset of a
larger dataset by Orellano et al. [30], thus, Kusznierz et
al. was excluded. Pregnancy was associated with de-
creased risk of influenza-associated mortality in univari-
ate analysis (OR 0.66, 95% CI 0.54–0.81; Table 3).
Antiviral use and influenza vaccination were also associ-
ated with a reduced risk of death (OR 0.77, 95% CI
0.63–0.96 and OR 0.50, 95% CI 0.32–0.78, respectively).
Older participants were at a significantly higher risk of
influenza-associated mortality (OR 1.24 per 5-year
Fig. 1 Flow chartLegend: IPD Individual patient data
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increase in age, 95% CI 1.19–1.29). Participants with dia-
betes (OR 2.06, 95% CI 1.54–2.75), any cardio-respira-
tory diseases (OR 1.41, 95% CI 1.11–1.81), and
immunocompromised status (OR 2.37, 95% CI 1.77–
3.18) were also found to be at higher risk.
In the primary multivariable model, pregnancy was no
longer significantly associated with a lower risk of
influenza-associated mortality (adjusted OR (aOR) 1.00,
95% CI 0.75–1.34) (Table 3). Antiviral usage (aOR 0.67,
95% CI 0.49–0.90) and vaccination (aOR 0.41, 95% CI
0.25–0.68) remained independently associated. Partici-
pants with diabetes (aOR 1.67, 95% CI 1.10–2.51) and
those with an immunocompromised status (aOR 2.35,
95% CI 1.56–3.55) remained at a higher risk. Also, each
Table 1 Characteristics of 36,498 eligible females 15–45 years of age with known pregnancy status
Author Eligible females (n) Pregnant (%) Mortality (%) Hospital admission(%) ICU admission(%) Country of origin Study Levelc
CDC/FluSurv-NETb [7–9] 2531 27.1 2.1 N/A 17.5 USA Hospital
CNISPb [10] 529 24.4 3.0 N/A 20.6 Canada Hospital
D’Ortenziob [11] 17 35.3 47.1 N/A N/A Réunion Island ICU
Echevarria-Zuno [12, 13] 25,206 6.0 1.1 9.9 11.8a Mexico Community
Fuhrmannb [14] 528 38.4 9.8a N/A 24.2a France Hospital/ICU
Harrisb [15] 51 54.9 2.0a 39.2 15.6a Australia Community
Helferty [16] 889 29.9 7.5a N/A 19.2 Canada Hospital
Huang [17] 141 7.1 5.7 N/A 24.1 Taiwan Hospital
Jain [18] 67 26.9 6 N/A 24.2 USA Hospital
Joves Sevic [19] 14 21.4 21.4 N/A N/A Serbia ICU
Kelly [20] 317 23.3 4.7 N/A 29.3 Australia Hospital
Kusznierz [21] 48 29.2 39.6 N/A 52.1 Argentina Hospital
Lehnersb [22] 56 51.8 0.0 55.4 10.7 Germany Community
Lenzid [23] 488 29.5 15 52.7 N/A Brazil Community
Limb [24] 197 41.1 1.5 N/A 5.6 Singapore Hospital
Malonda [25] 274 46.4 4.2a 86.9 11.1 Spain Community
Martin-Loechesb [26] 452 20.6 13.9 N/A N/A Spain ICU
Mehta [27] 36 16.7 13.9 N/A N/A India Hospital
Mulrennan [28] 22 22.7 0.0 N/A 22.7 Australia Hospital
Nishiokab 1557 25.8 11.1 N/A 24.6 Brazil Hospital
Oh [29] 176 11.9 0.6 N/A 4 South Korea Hospital
Orellano [30] 1689 7.1 2.7 60.5 N/A Argentina Community
Poeppl [31] 42 35.7 9.5 69 9.5 Austria Community
Riquelmeb [32] 73 52.1 8.3 72.6 16.4 Spain, Chile Community
Riquelmeb [33] 99 16.2 15.2 N/A 34.7 Global Hospital
Sertogullarindan [34] 9 22.2 22.2 N/A N/A Turkey ICU
Skarbinski [35] 68 42.6 7.7 N/A 25 USA Hospital
Thompson [36] 141 35.5 4.3 N/A 21.3 USA Hospital
Van’t Klooster [38] 339 19.5 0.9 N/A 9.7 Netherlands Hospital
Viasus [39] 210 46.7 2.4 N/A 10.5 Spain Hospital
Xu [40] 103 54.4 20.4 N/A 38.6 China Hospital
Yangb [41] 114 14.9 11.4 93 21.2 China Community
Zolotusca [42] 15 20.0 13.3 N/A 53.3 Romania Hospital
aNote percentages in Table 1 were based on valid data only; missing data were not included in the calculation
bAdditional data that was not included in the original publication was provided, unpublished data (Nishioka), and/or several publications based on the dataset
provided (CDC, CNISP). FluSurv-NET = Influenza Hospitalization Surveillance Network
cStudies were considered conducted in a ‘community’ setting if participants were seeking health care but have not yet been admitted to a hospital
dOnly a partial dataset available
N/A either no data available or not applicable, e.g. hospital admission as an outcome in a population that was hospitalized as an inclusion criterion for the study.
ICU: intensive care unit
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(n = 4379, 12.0%)
Non-pregnant
(n = 32,119, 88.0%)
Risk estimate (95% CI)
Mean age (years), SD 26.7 ± 6.1 29.2 ± 8.7 MD 2.43 (2.23–2.64)
Antiviral treatment 2073 (55.4%) 8452 (28.7%) OR 3.09 (2.88–3.31)
Vaccinateda 367 (12.1%) 2221 (7.8%) OR 1.62 (1.44–1.82)
Diabetes mellitus 150 (3.9%) 1094 (3.8%) OR 1.03 (0.86–1.22)
Cardio-respiratory 287 (7.7%) 2186 (7.5%) OR 1.03 (0.91–1.18)
Immunosuppressionc 74 (2.0%) 814 (2.8%) OR 0.69 (0.54–0.87)
Secondary model
Obesity 107 (4.3%) 963 (4.7%) OR 0.92 (0.75–1.13)
Smoking 77 (4.6%) 762 (3.3%) OR 1.43 (1.12–1.81)
Chronic respiratoryb 251 (6.9%) 1907 (6.6%) OR 1.05 (0.91–1.20)
Abbreviations: SD Standard deviation, MD Mean difference, OR Odds ratio
aVaccination status not included in the core model for the outcome ICU admission given > 20% missing data
b‘Chronic respiratory’ replaced ‘cardio-respiratory’ from the core model in the secondary analysis
c‘Immunosuppression’ includes participants with HIV positivity
All variables and figures in bold are indeed statistically significant
Table 3 Risk factors for death, hospitalization, and ICU admission in influenza infected women 15–45 years old (core model)
Variable Univariate analysis Multivariable analysisd
Odds ratio (95% CI) p-value Cases (studies) included Adjusted odds ratio (95% CI) p-value
Deatha
Age (per 5-year increase) 1.24 (1.19–1.29) < 0.001 35,591 (32) 1.19 (1.12–1.26) < 0.001
Pregnancy 0.66 (0.54–0.81) < 0.001 35,591 (32) 1.00 (0.75–1.34) 0.99
Antiviral (yes) 0.77 (0.63–0.96) 0.017 32,652 (31) 0.67 (0.49–0.90) 0.009
Vaccination 0.50 (0.32–0.78) 0.002 31,342 (26) 0.41 (0.25–0.68) < 0.001
Cardio-respiratory 1.41 (1.11–1.81) 0.006 32,167 (31) 1.30 (0.93–1.81) 0.12
Diabetes mellitus 2.06 (1.54–2.75) < 0.001 32,442 (31) 1.67 (1.10–2.51) 0.015
Immunosuppressione 2.37 (1.77–3.18) < 0.001 31,995 (29) 2.35 (1.56–3.55) < 0.001
Hospitalizationb
Age (per 5-year increase) 1.08 (1.06–1.10) < 0.001 27,972 (9) 1.12 (1.09–1.15) < 0.001
Pregnancy 5.33 (4.79–5.94) < 0.001 27,972 (9) 6.80 (6.02–7.68) < 0.001
Antiviral (yes) 0.96 (0.86–1.07) 0.45 25,814 (9) 1.01 (0.89–1.14) 0.89
Vaccination 0.88 (0.75–1.03) 0.11 27,225 (8) 0.91 (0.76–1.09) 0.31
Cardio-respiratory 2.24 (1.91–2.62) < 0.001 26,227 (9) 2.28 (1.91–2.73) < 0.001
Diabetes 1.00 (0.78–1.29) 0.99 25,185 (8) 0.92 (0.69–1.23) 0.59
Immunosuppressione 1.16 (0.82–1.65) 0.41 25,214 (9) 1.05 (0.69–1.60) 0.83
ICUc Admissionc
Age (per 5-year increase) 1.16 (1.13–1.20) < 0.001 8836 (26) 1.07 (1.03–1.11) 0.003
Pregnancy 0.65 (0.57–0.74) < 0.001 8836 (26) 0.57 (0.48–0.69) < 0.001
Antiviral (yes) 1.73 (1.48–2.01) < 0.001 7769 (26) 1.96 (1.63–2.35) < 0.001
Cardio-respiratory 1.39 (1.19–1.63) < 0.001 7152 (26) 1.22 (1.01–1.48) 0.043
Diabetes 1.81 (1.48–2.21) < 0.001 8019 (26) 1.58 (1.26–1.99) < 0.001
Immunosuppressione 1.45 (1.18–1.78) < 0.001 7516 (24) 1.09 (0.86–1.39) 0.48
aMultivariable participants count: 26964, 24 studies, bMultivariable participants count: 23450, 7 studies, cMultivariable participants count: 5766, 24 studies
dAll variables listed were included in each of the three (death, hospitalization, or ICU admission) multivariable models
e‘Immunosuppression’ includes participants with HIV positivity
All variables and figures in bold are indeed statistically significant
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additional 5-year increase in age increased the risk of in-
fluenza-associated mortality (aOR 1.19, 95% CI 1.12–
1.26).
Similarly, pregnancy was not significantly associated with
death in the multivariate post hoc subgroup analyses,
whether in community-based (aOR 1.01, 95% CI 0.68–1.51),
nor in hospital-based studies (aOR 0.85, 95% CI 0.45–1.59).
Of the additional variables considered in the secondary
analysis, obesity was independently associated with an
increased risk of influenza-associated mortality (aOR
1.72, 95% CI 1.17–2.52) along with smoking (aOR 1.84,
95% CI 1.04–3.25). The lack of association between
pregnancy and influenza-associated mortality persisted
when additional covariates were added in the sensitivity
analysis, with the exception when smoking status was
added to the model resulting in a higher risk for death
in pregnant women (aOR 1.62, 95% CI 1.03–2.56)
(Table 4).
Influenza-associated hospitalization
Nine of 33 studies (27%) reported on influenza-associated
hospital admission with outcome data available for 27,699
participants. Four of the studies were conducted in Eur-
ope, two in Australia, and one each in Brazil, China, and
Mexico. Pregnant women were at a significantly increased
risk for hospitalization compared to non-pregnant women
in the univariate analysis (OR 5.33, 95% CI 4.79–5.94)
(Table 3). Participants with cardio-respiratory diseases
were also more likely to be admitted to the hospital (OR
2.24, 95% CI 1.91–2.62) along with older age (OR 1.08,
95% CI 1.06–1.10 per 5-year increase). No significant as-
sociations were found for the other potential risk factors,
and antiviral usage and vaccination status were not found
to be protective. In the multivariable analysis, pregnancy
remained associated with a seven times increase in risk for
influenza-associated hospital admission (aOR 6.80, 95% CI
6.02–7.68). The risk increased by 12% (95% CI 1.09–1.15)
per 5-year increase in age and any cardio-respiratory dis-
eases were also associated with an increased risk (aOR
2.28, 95% CI 1.91–2.73).
Of the additional variables considered in the secondary
analysis, only obesity and chronic respiratory diseases
were significantly associated with hospital admission.
Pregnancy remained a significant risk factor for hospital
admission when these variables were added to the model
(Table 4).
Influenza-associated ICU admission
Data for influenza-associated ICU admission was re-
ported in 26 out of 33 (79%) studies with outcome data
available for 9166 participants. The majority of studies
were conducted in Europe (n = 8, 30.8%), followed by
studies from North America (n = 7, 26.9%), and Asia
(n = 5, 19.2%). Pregnancy was associated with a reduced
risk for ICU admission in the univariate analysis (OR
0.65, 95% CI 0.57–0.74). Older age by 5-year increase
(OR 1.16, 95% CI 1.13–1.20), cardio-respiratory co-mor-
bidities (OR 1.39, 95% CI 1.19–1.63), diabetes (OR 1.81,
95% CI 1.48–2.21), immunosuppression (OR 1.45, 95%
CI 1.18–1.78) and antiviral usage (OR 1.73, 95% CI
1.48–2.01) were associated with an increased risk of ICU
admission (Table 3).
In the multivariable model, pregnancy remained
significantly associated with a decreased risk of ICU
admission (OR 0.57, 95% CI 0.48–0.69). The point
estimates for the other variables were similar; however,
Table 4 Risk factors for death, hospitalization, and intensive-care unit (ICU) admission in influenza infected women 15–45 years old
in the secondary and sensitivity analyses
Death Hospital admission ICU admission
Variable Adjusted odds ratio (95% CI) p-value Adjusted odds ratio
(95% CI)
p-value Adjusted odds ratio
(95% CI)
p-value
Obesity 1.72 (1.17–2. 52) 0.005 1.49 (1.15–1.93) 0.002 2.93 (1.99–4.31) < 0.001
Smoking 1.84 (1.04–3.25) 0.036 0.93 (0.71–1.22) 0.60 1.56 (0.81–3.00) 0.18
Chronic respiratory 0.92 (0.61–1.37) 0.67 2.30 (1.92–2.75) < 0.001 1.20 (0.96–1.49) 0.10
Sensitivity Analysis
Pregnancy (core modelj) 1.00 (0.75–1.34) 1.00 6.80 (6.02–7.68) < 0.001 0.57 (0.48–0.69) < 0.001
Pregnancy (core model including obesity) 0.99 (0.71–1.38)a 0.93 6.83 (6.05–7.71)d < 0.001 0.91 (0.66–1.25)g 0.56
Pregnancy (core model including Smoking) 1.62 (1.03–2.56)b 0.038 7.86 (6.94–8.90)e < 0.001 0.59 (0.35–0.99)h 0.047
Pregnancy (core model including
chronic respiratory)
0.99 (0.74–1.32)c 0.93 6.40 (5.58–7.33)f < 0.001 0.57 (0.47–0.68)i < 0.001
a18542, 21 studies, b23064, 7 studies, c26948, 23 studies
d17505, 7 studies, e22846, 4 studies, f23438, 6 studies
g 2087, 20 studies, h1069, 11 studies, i5683, 23 studies
jVariables included in the core model were age, antiviral use, vaccination (with the exception of ICU admission), cardio-respiratory illness, diabetes,
and immunosuppression
All variables and figures in bold are indeed statistically significant
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immunosuppression was no longer significantly associ-
ated (OR 1.09, 95% CI 0.86–1.39) with ICU admission.
In the primary analysis, the comparison group for ICU
admission was –depending on data availability- partici-
pants who at baseline were admitted to a hospital but
not to the ICU (n = 309, 4,2% of participants), partici-
pants known at baseline to be not admitted to a hospital
(n = 826, 11.1%) or participants with no information on
hospital admission status but information on ICU ad-
mission status (n = 6298, 84.7%). In our post-hoc sub-
group analyses, the association seemed to be driven by
studies conducted in hospitalized patients (aOR 0.57,
95% CI 0.46–0.70), while there was no significant associ-
ation with ICU admission in community-based studies
(aOR 0.72, 95% CI 0.42–1.23).
In our secondary analyses, only obesity was associated
with significantly increased risk of ICU admission (aOR
2.93, 95% CI 1.99–4.31). When obesity was included in
the model, pregnancy was no longer significantly associ-
ated (aOR 0.91, 95% CI 0.66–1.25) (Table 4). Vaccination
status was not associated with the risk for ICU admis-
sion (aOR 0.78, 95% CI 0.59–1.03).
Discussion
In our IPD meta-analysis, pregnancy was associated with
a seven times higher risk of hospitalization but, among
patients seeking medical care as in-or outpatients, was
not found to be independently associated with influ-
enza-associated mortality, after adjusting for other po-
tential risk factors in multivariable analysis. These
findings are consistent with previous systematic reviews/
meta-analyses [4, 5]. However, this study could not ad-
dress whether a true community based cohort of preg-
nant women is at higher risk of influenza associated
complications.
One explanation for our findings is that pregnant
women may be more likely to seek care and be preferen-
tially admitted to a hospital because of concerns that
they are at higher risk for complications, particularly in
the high resource settings where most of the included
studies were conducted. The fact that pregnant women
were not found to be at increased risk for death or ICU
admission despite a higher hospital admission rate would
support such an explanation. Similarly, pregnant women
being considered to be at higher risk may explain the
observation that pregnant women were more likely to be
treated with antivirals and were more likely vaccinated.
While our multivariable analysis accounted for comor-
bidities, vaccination status, and antiviral treatment,
potential selection bias could not be controlled for. Most
of our data were from hospitalized cohorts, a group in
which non-severely ill pregnant women may have been
overrepresented -if there was a lower threshold to test
for influenza and admit women with influenza if
pregnant. While precautionary influenza hospitalizations
may be preventable with influenza vaccination, this is
currently not supported by the available evidence. Fur-
thermore, our data did not provide consistent support
for pregnancy being an independent risk factor for se-
vere influenza disease across outcomes. The direction of
the association was not consistent among the three out-
comes: in the primary analysis, there was a significantly
increased risk for hospitalization, a significantly de-
creased risk for ICU admission, and no significant risk
for mortality. These findings are in keeping with previ-
ously published systematic reviews [4, 5] and strengthen
these findings given the adjustment for individual-level
characteristics in this study. It is important to note how-
ever, that severe outcomes may not have appeared to be
greater in hospitalized pregnant women simply because
they were compared to a relatively ill comparison group.
However, if pregnant women were admitted to hospital
because they were more seriously ill, and not because of
a precautionary measure, it is possible that the similar
incidence of adverse outcomes would present an in-
creased risk compared to the source population, preg-
nant women living in the community. Most of our
sensitivity analyses were corroborating the findings from
the primary analysis, with one notable exception being
the multi-variable analysis that included smoking status
which suggested a higher mortality rate in pregnant
women. This must be interpreted in the light of all other
sensitivity analyses corroborating the primary analysis,
and the fact that 37% of participants and 79% of studies
were excluded from this analysis due to missing data. Of
note, there was an association between use of antivirals
and a higher likelihood of ICU admission which is most
likely due to confounding by indication.
As already outlined in a previous systematic review,
the majority of ecological studies suggest more severe
outcomes in pregnant women, while a meta-analysis of
individual-patient studies did not [5]. The findings in
this IPD-meta analysis corroborate the findings of the
meta-analysis and contradict most of the ecological
studies. As discussed elsewhere, this is most likely re-
lated to biases in ecological studies such as use of a
population-wide comparator, estimation of pregnancy
rates, and lack of tracking of live and still births [5].
Strengths of this review were the extensive quantity of
data included along with the breadth of studies and risk
factors examined. The IPD allowed us to evaluate
pregnancy as an independent risk factor while adjusting
for several patient characteristics including comorbidi-
ties. The main limitation of our meta-analysis was the
potential for selection bias in source studies, where preg-
nant women enrolled in the studies might have been less
ill than non-pregnant women and no studies where
women living in the community were followed until
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hospitalization and afterwards to assess for severe out-
comes. Missing data among participants for some covar-
iates was yet another limitation. Furthermore, risk
factors may have been defined differently across studies,
e.g. the diagnosis of obesity would optimally be based on
the body mass index prior to being pregnant. In
addition, differences in patient populations resulted in
clinical heterogeneity which resulted in statistical hetero-
geneity as shown in our aggregate data systematic review
[5]. Furthermore, it is possible that pregnant women
were in general healthier than non-pregnant women, be-
cause a minimum level of health is needed to become
pregnant. However, the multivariate analysis adjusted for
this to the extent possible given the binary data. Data on
timing of the antivirals in respect to the outcomes were
not available, thus, we are unable to presume causality
for any of the associations between antivirals and the
clinical outcomes. The risk for severe outcomes may
vary by trimester which could not be analyzed given the
lack of data available. We were able to obtain 31% of the
IPD, only, which could have resulted in a selection bias.
However, the study characteristic of in- and excluded
studies were similar as were the key findings when com-
pared to the previously published systematic review [5].
An updated search may have identified more studies of
potential relevance, but given the time consuming
process of obtaining IPD, no update of the literature
search while working on this IPD meta-analysis was con-
ducted. Finally, most of the available data were from
studies conducted during the 2009 H1N1 pandemic and
from high-income countries, thus, the generalizability of
our findings to seasonal influenza and low-and middle
income countries is unclear.
Conclusions
Our study found a higher risk of influenza associated
hospitalization among pregnant women as compared to
non-pregnant women. We did not find a higher mortal-
ity rate or higher likelihood of ICU admission among
pregnant women who sought medical care as in- or out-
patients. However, this study did not address whether a
true community based cohort of pregnant women is at
higher risk of influenza associated complications. To ad-
dress this question, a cohort study of pregnant and non-
pregnant women with a study population representative
of the community who are infected with influenza would
need to be conducted.
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